Alzheimer's Disease
Filter News
Found 999 articles
-
Alzheon CEO Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation for Significant Contribution Towards Research and Treatment of Alzheimer’s Disease, and Donated Cash Prize to INDRC Institute
1/3/2024
Alzheon, Inc. announced that its Founder, President & CEO Dr. Martin Tolar has been awarded the Eliška and Zdeněk Strmiska Award from the Alzheimer’s Foundation for significant contribution towards the research and treatment of Alzheimer’s disease.
-
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
12/27/2023
NKGen Biotech Inc. announced that it has received a No Objection Letter from Health Canada for its Clinical Trial Application for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer cell therapy for treatment of patients with moderate Alzheimer’s Disease.
-
WRQ Sciences and Superfluid Dx., Inc. Announce Completion of Oversubscribed Series A Financing in Breakthrough Alzheimer's Disease Diagnostic Company Superfluid Dx
12/20/2023
WRQ Sciences and Superfluid Dx, Inc., announced the completion of an oversubscribed Series A financing led by WRQ Sciences.
-
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
12/19/2023
Anavex Life Sciences Corp. announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agency’s centralised procedure.
-
LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20
12/13/2023
BioArctic AB's partner Eisai announced that LEQEMBI will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance drug price list.
-
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
12/11/2023
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today reported third quarter 2023 financial results and provided operational highlights.
-
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
12/11/2023
Cognito Therapeutics announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease.
-
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
12/11/2023
Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-PTSD01, a Phase IIA clinical study of AL001 for treatment of patients with PTSD.
-
The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
-
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
12/7/2023
10x Genomics, Inc., a leader in single cell and spatial biology, announced a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias to build a more comprehensive single cell atlas of the human brain to further neuroscience research.
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
12/6/2023
Synaptogenix, Inc. announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences.
-
For forms of Alzheimer’s, frontotemporal dementia and Parkinson’s caused by genetic defects, gene therapy could change the treatment landscape.
-
Diadem to Discuss Biomarker Blood Tests for Alzheimer's Disease at TD Cowen Liquid Biopsy Summit
12/4/2023
Diadem SpA, (Diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to Alzheimer's disease (AD), today announced that Chief Executive Officer Paul Kinnon will participate in the TD Cowen Liquid Biopsy Summit, to be held at the Mandarin Oriental Hotel in New York City on December 5, 2023.
-
SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, an oral therapeutic for Alzheimer's disease and other neurodegenerative diseases
11/30/2023
SciNeuro Pharmaceuticals today announced the completion of dosing in its Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study.
-
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
11/29/2023
BioVie Inc. today announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate Alzheimer’s Disease (AD).
-
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
11/27/2023
INmune Bio, Inc. announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.
-
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease
11/27/2023
ADvantage Therapeutics, Inc. today announced the first patient enrolled in the Company’s European Phase 2b clinical trial on its lead candidate, AD04™ for the treatment of mild Alzheimer’s disease (AD).
-
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
11/27/2023
Annovis Bio, Inc. announced that AD phase II/III study of its lead compound buntanetap has exceeded full enrollment.
-
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
11/20/2023
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced that representatives of Anavex met with team members of the European Medicines Agency.
-
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
11/20/2023
ProMIS Neurosciences Inc. today announced that the Company dosed the first subjects in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for Alzheimer’s disease (AD).